Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to … C Fitzmaurice, C Allen, RM Barber, L Barregard, ZA Bhutta, H Brenner, ... JAMA oncology 3 (4), 524-548, 2017 | 7154 | 2017 |
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 KB Tran, JJ Lang, K Compton, R Xu, AR Acheson, HJ Henrikson, ... The Lancet 400 (10352), 563-591, 2022 | 435 | 2022 |
Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017 SL James, CD Castle, ZV Dingels, JT Fox, EB Hamilton, Z Liu, ... Injury Prevention 26 (Suppl 2), i96-i114, 2020 | 285 | 2020 |
Current approaches for combination therapy of cancer: the role of immunogenic cell death Z Asadzadeh, E Safarzadeh, S Safaei, A Baradaran, A Mohammadi, ... Cancers 12 (4), 1047, 2020 | 127 | 2020 |
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy A Derakhshani, Z Rezaei, H Safarpour, M Sabri, A Mir, MA Sanati, ... journal of cellular physiology, 2020 | 114 | 2020 |
Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study DSS Hemmat Nima , Derakhshani Afshin , Bannazadeh Baghi Hossein , Silvestris ... Frontiers in Genetics, 2020 | 103 | 2020 |
Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials O Kooshkaki, A Derakhshani, N Hosseinkhani, M Torabi, S Safaei, ... International journal of molecular sciences 21 (12), 4427, 2020 | 89 | 2020 |
Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies? N Hosseinkhani, A Derakhshani, O Kooshkaki, M Abdoli Shadbad, ... International Journal of Molecular Sciences 21 (21), 8305, 2020 | 84 | 2020 |
The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV N Hemmat, Z Asadzadeh, NK Ahangar, H Alemohammad, B Najafzadeh, ... Archives of Virology 166, 675-696, 2021 | 82 | 2021 |
Mast cells: A double-edged sword in cancer A Derakhshani, F Vahidian, M Alihasanzadeh, A Mokhtarzadeh, ... Immunology letters 209, 28-35, 2019 | 81 | 2019 |
Interactions between cancer stem cells, immune system and some environmental components: friends or foes? behzad baradaran fatemeh Vahidian, Pascal Duijf, Elham Safarzadeh, afshin ... Immunology Letter, 2019 | 70 | 2019 |
Cytotoxic T-lymphocyte antigen-4 in colorectal cancer: another therapeutic side of capecitabine A Derakhshani, S Hashemzadeh, Z Asadzadeh, MA Shadbad, ... Cancers 13 (10), 2414, 2021 | 68 | 2021 |
Pancreatic cancer signaling pathways, genetic alterations, and tumor microenvironment: The barriers affecting the method of treatment D Javadrashid, A Baghbanzadeh, A Derakhshani, P Leone, N Silvestris, ... Biomedicines 9 (4), 373, 2021 | 62 | 2021 |
Arginase 1 (Arg1) as an Up-Regulated Gene in COVID-19 Patients: A Promising Marker in COVID-19 Immunopathy A Derakhshani, N Hemmat, Z Asadzadeh, M Ghaseminia, MA Shadbad, ... Journal of clinical medicine 10 (5), 1051, 2021 | 51 | 2021 |
The positive and negative immunoregulatory role of B7 family: promising novel targets in gastric cancer treatment N Bolandi, A Derakhshani, N Hemmat, A Baghbanzadeh, Z Asadzadeh, ... International Journal of Molecular Sciences 22 (19), 10719, 2021 | 50 | 2021 |
MiR-144: a new possible therapeutic target and diagnostic/prognostic tool in cancers O Kooshkaki, Z Rezaei, M Rahmati, P Vahedi, A Derakhshani, O Brunetti, ... International journal of molecular sciences 21 (7), 2578, 2020 | 49 | 2020 |
COVID-19 infection in cancer patients: how can oncologists deal with these patients? O Brunetti, A Derakhshani, B Baradaran, A Galvano, A Russo, N Silvestris Frontiers in Oncology 10, 734, 2020 | 44 | 2020 |
The role of V-domain Ig suppressor of T cell activation (VISTA) in cancer therapy: lessons learned and the road ahead N Hosseinkhani, A Derakhshani, MA Shadbad, A Argentiero, V Racanelli, ... Frontiers in Immunology 12, 676181, 2021 | 43 | 2021 |
The latest findings of PD-1/PD-L1 inhibitor application in gynecologic cancers O Kooshkaki, A Derakhshani, H Safarpour, S Najafi, P Vahedi, O Brunetti, ... International journal of molecular sciences 21 (14), 5034, 2020 | 39 | 2020 |
A systematic review on the therapeutic potentiality of PD-L1-inhibiting microRNAs for triple-negative breast cancer: Toward single-cell sequencing-guided biomimetic delivery MA Shadbad, S Safaei, O Brunetti, A Derakhshani, P Lotfinejad, ... Genes 12 (8), 1206, 2021 | 37 | 2021 |